



Medicine: darolutamide (brand name: Nubeqa®)

Bayer plc

The Scottish Medicines Consortium (SMC) has assessed darolutamide for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC). It is for use in men who are at high risk of developing metastatic disease. This document summarises the SMC decision and what it means for patients.

What has SMC said?

After careful consideration, SMC has accepted darolutamide for the treatment of prostate cancer as described above.

This SMC advice takes into account a confidential discount offered by the pharmaceutical company that improves the cost-effectiveness of darolutamide.

What does SMC's decision mean for patients?

If your healthcare professional thinks that darolutamide for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland.



What is darolutamide used for?

Darolutamide is used to treat prostate cancer that has got worse despite treatments to decrease the production of a male hormone called testosterone. This is known as castration-resistant prostate cancer (CRPC). Darolutamide is used specifically to treat patients with CRPC whose cancer is not metastatic (spread to other parts of the body), but is at a high risk of spreading.

How does darolutamide work?

Prostate cancer cells need male hormones to grow and survive. Darolutamide blocks the actions of male hormones called androgens, including testosterone, which helps slow down the growth of the cancer.

How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC consider the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- The potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of darolutamide by looking at the SMC Detailed Advice Document (SMC2297).

More information

The organisations below can provide more information and support for people with prostate cancer and their families. SMC is not responsible for the content of any information provided by external organisations.

Prostate Cancer UK



<http://www.prostatecanceruk.org>



0800 074 8383

Prostate Scotland



<http://www.prostatescotland.org.uk>



0131 603 8660

Tackle Prostate Cancer



<http://www.tackleprostate.org>



0800 035 5302

You can find out more about darolutamide (Nubeqa®) in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>